RxDoctor Payments Data

Ruben Villa, MD

Nephrology · Lubbock, TXNPI 1659367647

Payments from drug & device makers

$28,970in general payments, 2019–2025

Across 99 payments — averaging $292.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$16K
  • Humacyte Global, Inc.$10K
  • Boston Scientific$1K
  • Otsuka America Pharmaceutical, Inc.$350
  • Nxstage Medical, Inc.$231
  • Fresenius USA Marketing, Inc.$116
  • plus $543 from 13 others

What the payments were for

  • Speaking & faculty fees$14,54177%
  • Travel & lodging$2,08111%
  • Food & beverage$2,08211%
  • Education$860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,970 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$492,498
Medicare patients
466
Services billed
5,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide136$443,940
AuryxiaFerric Citrate20$41,502
MounjaroTirzepatide25$25,734
Lanthanum Carbonate11$20,582
OzempicSemaglutide16$15,320
Sevelamer Carbonate80$11,379
KerendiaFinerenone12$7,599
Midodrine Hcl34$1,739
Calcium Acetate22$1,550
Nifedipine ErNifedipine30$623
Lidocaine-PrilocaineLidocaine/Prilocaine35$563
Furosemide78$428
Pantoprazole Sodium35$410
Amlodipine Besylate88$347
Hydralazine Hcl28$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$116$443,940136 claims
Akebia Therapeutics IncAuryxia$55$41,50220 claims
BayerKerendia$16,370$7,59912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →